-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1

Benzinga·11/02/2026 08:24:04
Listen to the news
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.